Tetraphase Pharmaceuticals Inc. (TTPH)’s Financial Results Comparing With MeiraGTx Holdings plc (NASDAQ:MGTX)

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) and MeiraGTx Holdings plc (NASDAQ:MGTX) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tetraphase Pharmaceuticals Inc. 18.29M 2.20 70.07M -1.37 0.00
MeiraGTx Holdings plc N/A 908.58 85.59M -3.15 0.00

Table 1 demonstrates Tetraphase Pharmaceuticals Inc. and MeiraGTx Holdings plc’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us Tetraphase Pharmaceuticals Inc. and MeiraGTx Holdings plc’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tetraphase Pharmaceuticals Inc. -383.11% 0% 0%
MeiraGTx Holdings plc 0.00% -150.6% -91.4%

Liquidity

Tetraphase Pharmaceuticals Inc.’s Current Ratio is 7.3 while its Quick Ratio is 7.1. On the competitive side is, MeiraGTx Holdings plc which has a 4.8 Current Ratio and a 4.8 Quick Ratio. Tetraphase Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to MeiraGTx Holdings plc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Tetraphase Pharmaceuticals Inc. and MeiraGTx Holdings plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Tetraphase Pharmaceuticals Inc. 0 0 2 3.00
MeiraGTx Holdings plc 0 0 0 0.00

Tetraphase Pharmaceuticals Inc.’s upside potential currently stands at 641.84% and an $5.5 consensus price target.

Institutional & Insider Ownership

Roughly 43.3% of Tetraphase Pharmaceuticals Inc. shares are held by institutional investors while 26.5% of MeiraGTx Holdings plc are owned by institutional investors. 0.5% are Tetraphase Pharmaceuticals Inc.’s share held by insiders. Competitively, 19.39% are MeiraGTx Holdings plc’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tetraphase Pharmaceuticals Inc. -17.85% -22.89% -26.75% -59.49% -76.24% -22.21%
MeiraGTx Holdings plc 20.04% 12.68% 74.82% 71.85% 0% 130.5%

For the past year Tetraphase Pharmaceuticals Inc. had bearish trend while MeiraGTx Holdings plc had bullish trend.

Summary

On 7 of the 10 factors Tetraphase Pharmaceuticals Inc. beats MeiraGTx Holdings plc.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a second-generation Gram-negative program, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. In addition, the company is involved in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.

MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.